S. Gail Eckhardt, MD, FASCO

S. Gail  Eckhardt S. Gail Eckhardt, MD, FASCO, is the inaugural director of the LIVESTRONG Cancer Institutes (LCI) at the University of Texas at Austin. Since taking on this role in 2017, Dr. Eckhardt has led the developing center in recruiting over 54 full members into four programs with over 11 million in cancer-related peer-reviewed funding. Prior to her recruitment to Texas, Dr. Eckhardt served in leadership roles at the NCI-designated University of Colorado Comprehensive Cancer Center, including writing the first competitive submission for the Developmental Therapeutics Program as program leader (10 years) and as associate director of translational research (seven years). She also served on the NCI IRG-A, Cancer Centers Study Section from 2010-2015 and currently sits on 11 NCI-Designated Cancer Center external advisory boards (EAB) and one NCI SPORE EAB. 

Dr. Eckhardt was division head of Medical Oncology at the University of Colorado for eight years. She is a board-certified medical oncologist with a disease focus of GI malignancies and over 25 years of experience in early phase clinical trials and preclinical research.  

Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, and the FDA Oncology Drugs Advisory Committee, and currently serves on the NCI Investigational Drug Steering Committee and Cancer Research UK’s New Agents Committee and Translational Research Panel. She recently served as lead mentor in ASCO’s Leadership Development Program.

Dr. Eckhardt is a Cancer Prevention and Research Institute of Texas (CPRIT) Scholar and the principal investigator on grants involving early clinical trials and colorectal cancer research. She has conducted numerous Phase I and II clinical trials and has published over 200 manuscripts. Her area of interest is in the preclinical and early clinical development of combinations of molecularly targeted compounds, with a laboratory focus on colorectal cancer.